Hepalife Technologies Inc.

60 State St
Ste 700
Boston
MA
02109
United States
(800) 518-4879
Product(s): 
Develops a bioartificial liver device, HepaLife, to treat liver failure using a patented PICM-19 liver stem cell line; and testing platforms to improve the evaluation of drug toxicity and side effects
Ownership: 
Public
Exchange: 
OTC BB
symbol: 
HPLF.OB
Yahoo Quotes: 

Chairman: 
Frank Menzler
President: 
Frank Menzler
CEO: 
Frank Menzler
Management: 
Donna A. Lopolito, CFO
Shawn P. Cain, director-product development
Richard E. Kruger, director-regulatory affairs
Hepalife Technologies Inc.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp